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questions looked into the skin condition, and one question described the localization 
of possible lesions on the skin. Moreover, a psychometric validation has enable to 
conﬁrm the internal consistency and very good reproducibility of the questionnaire 
CONCLUSIONS: The ongoing validation study carried in several dermatology hos-
pital units will allow to determine 3 levels of presumed diagnosis of Atopic Dermatitis: 
«unlikely», «likely» or «possible»; which will help the caregiver decide whether the 
patient should be referred to a dermatologist to get appropriate treatment.
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OBJECTIVES: To develop a brief self-administered questionnaire able to measure 
patient satisfaction with treatments of skin diseases of the hands, with good psycho-
metric properties. METHODS: An initial version of the questionnaire composed by 
38 items, organized in 6 dimensions, was proposed. Items were extracted from 3 
patient’s focus-groups and ratiﬁed by a 7 expert panel and were presented to a pilot 
sample to test comprehension. This full version was administered to a sample of 217 
patients with skin diseases of the hands recruited at 18 representative hospitals in 
Spain. In order to assess convergent validity Morisky-Green compliance scale, SF-12 
HRQoL questionnaire and a health status VAS were also used. Treatment effectiveness 
and tolerability were also measured. Exploratory factor analysis was used for item 
reduction and conﬁrmatory factor analysis for dimensionality assessment. Internal 
consistency and split-half methods were used for reliability. Item discrimination and 
kwon group’s validity (gender, age, severity, and treatment) were also assessed. 
RESULTS: The reduction and validation sample was composed by 54% women, and 
a mean age of 43 years (sd  13.7). Questionnaire was reduced to 17 items arranged 
in 6 dimensions: Efﬁcacy, Ease of use, Impact on HRQoL, Follow up, Undesired 
Effects, General Opinions. Cronbach’s alpha attained a 0.9 value. Dimensions exhib-
ited levels of correlation different from those found previously from questionnaires 
for other pathologies. The overall score distributed normally with 58.4 mean 
(sd  18.01). Dimension scores correlated within 0.003 and 0.222 with HQoL measures, 
correlated higher with effectiveness (r  0.41) and tolerability (0.22), but very low 
with compliance (0.015). Signiﬁcant differences were found between some diagnoses 
and treatments. CONCLUSIONS: The reduced questionnaire presents good psycho-
metric properties, with an excellent reliability and good initial validity evidences.
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OBJECTIVES: Skin scars impact quality of life (QoL), quantiﬁcation of which is 
essential to evaluate the effectiveness of treatment. As no suitable instruments were 
available the objective of the study was to develop and validate the ﬁrst patient-reported 
scale of scar-speciﬁc symptoms and QoL. METHODS: Questionnaire content was 
derived from qualitative interviews with UK scar patients. Face and content validity 
were assessed by cognitive debrieﬁng interviews conducted with patients. The ﬁnal 
instrument was determined using Rasch analysis and psychometrically assessed in a 
validation survey. RESULTS: Five hundred and sixty-seven potential items were 
extracted from 34 qualitative interview transcripts. Following review and reduction, 
16 symptom and 36 QoL items were identiﬁed. The draft scales were found to be rel-
evant, clear and easy to use in 16 patient interviews. Two QoL items were deleted as 
patients considered them too extreme. Following the validation survey (n  103), 10 
QoL and 3 symptom items were removed: eight misﬁt the Rasch model (Chi2 p  
0.05); four were redundant and one functioned differently according to age. Rasch 
analysis conﬁrmed two unidimensional scales (p  0.05). Internal consistency was good    
for both the symptoms and QoL scales (0.84 and 0.85) as was test-retest reliability 
(0.83 and 0.89 respectively). The symptom scale was shown to be statistically signiﬁ-        
cantly related (as expected) to scores on the Hospital Anxiety and Depression Scale 
(HADS) and the clinician-completed Manchester Scar Score (MSS). The QoL scale 
was also statistically signiﬁcantly related to scores on these measures and on patient-
reported scar severity. CONCLUSIONS: PRISM is the ﬁrst scientiﬁcally rigorous 
patient-reported instrument designed speciﬁcally for scar patients. It consists of two 
unidimensional scales with good psychometric and scaling properties: QoL (24 items) 
and symptoms (13 items). PRISM is well accepted by patients, easy to use and should 
prove valuable for assessing scar disease severity in clinical trials and practice.
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OBJECTIVES: The Quality of Life (QoL) impact of chronic hand eczema (CHE) is 
expected to be signiﬁcant because of the high functional, social and psychological 
impact of this disease but has rarely been assessed with validated tools. This study 
determined the effect of CHE severity on patient QoL by the Dermatology Life Quality 
Index (DLQI). METHODS: Data from a Phase II study of oral alitretinoin for the 
treatment of moderate to severe CHE unresponsive to potent topical corticosteroids 
was used to measure changes in QoL according to Physician’s Global Assessment 
(PGA) of disease severity. 162 matched DLQI and PGA observations were analysed 
using mixed models. The PGA is a global 5-point rating of CHE severity based on 
multiple signs and symptoms. The DLQI is a simple questionnaire validated in several 
skin diseases and different languages. Ten questions scored 0–3 are summed, with a 
total score of 0 (best QoL) to 30 (worst QoL). DLQI  5 is considered clinically sig-
niﬁcant and DLQI 11–20 is considered to indicate a very large impact of skin disease 
on QoL. RESULTS: Increasing severity of CHE was associated with a conditional 
mean DLQI score as follows: ‘clear/almost clear’ 1.74, ‘mild’ 5.93, ‘moderate’ 9.78, 
and ‘severe’ 15.08. Changes in DLQI score from PGA ‘severe’ to milder states during 
the 12 week study were as follows: ‘moderate’ (5.30), ‘mild’ (9.15), ‘almost clear’ 
(12.03), and ‘clear’ (14.56). All changes were statistically signiﬁcant (p  0.0001) 
and exceeded the Minimal Important Difference (MID) for CHE estimated to be 2.53 
in a recent German observational study. CONCLUSIONS: The QoL of patients with 
CHE is signiﬁcantly inﬂuenced by clinical disease severity as measured by the PGA 
instrument. Treatment which reduces clinical severity of CHE is likely to be worth-
while from the patient perspective in view of the signiﬁcant improvement in QoL that 
may result.
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BACKGROUND: Recent studies have demonstrated the efﬁcacy of adalimumab on 
improving psoriasis symptoms, health related quality of life (HRQoL), and depression. 
OBJECTIVES: To quantify the importance of depression on overall HRQoL in 
patients with active plaque psoriasis who were enrolled in an open label clinical study 
of adalimumab. METHODS: PRIDE (A Canadian Open-Label Access PRogram to 
Evaluate the Safety and the Effectiveness of Adalimumab When Added to InaDEquate 
Therapy for the Treatment of Psoriasis) was an open-label, multicenter, Phase IIIb 
study in Canada. Patients with active moderate to severe plaque psoriasis who failed 
to respond to, or were intolerant of, standard prior therapies received adalimumab 
(80 mg) at Week 0 followed by adalimumab (40 mg) every other week. Changes in               
the outcomes including the Psoriasis Area and Severity Index (PASI), Beck Depression 
Inventory-II (BDI) and EQ-5D VAS at baseline, weeks 16 and 24 were evaluated. A 
multivariate mixed-effect regression was ﬁtted to identify the independent contribution 
of skin severity (PASI) and depression (BDI) on HRQoL (EQ-5D VAS). RESULTS: A 
total of 203 patients (61% male, mean age:46, mean PASI:20) were enrolled at 26 
sites. Statistically signiﬁcant improvements in PASI, EQ-5D VAS and BDI were seen 
at week 16 (improvements of 16.0, 10.1, 4.2, respectively all p  0.001) and 24 
(improvements of 16.1, 10.7, 4.3, respectively all p  0.001). The model found that 
both PASI (B  0.40, p  0.004) and BDI (B  0.54, p  0.002) were independent 
predictors of EQ-5D VAS. The interaction between BDI and females was also signiﬁ-
cant (B  0.64, p  0.006). CONCLUSIONS: HRQoL in patients with plaque psoria-
sis is inﬂuenced independently by both skin severity and depression. While the etiology 
of depression is likely through skin severity, it appears likely that both contribute to 
the improvements in HRQoL seen with adalimumab treatment.
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OBJECTIVES: There is limited data available on the economical burden of psoriasis 
and its impact on everyday life from the patient perspective. The aim of the study was 
to measure the burden of psoriasis for the patient. METHODS: We performed 
a cross-sectional study in French psoriasis patients. All patients aged q18 years 
with a diagnosis of plaque-psoriasis conﬁrmed by a physician were included. A self-
administered questionnaire evaluating everyday life was constructed with members of 
the French association of psoriasis patients. In addition the Dermatology Life Quality 
Index (DLQI), Working Productivity and Activity Impairment (WPAI) and individual 
costs were assessed. RESULTS: A total of 590 patients completed the survey. Mean 
age of the responders was 56 years. The mean DLQI score was 8.5 for patients with 
severe psoriasis versus 6.4 for mild psoriasis. Global loss of productivity was 10.7% 
without signiﬁcant difference according to the disease severity. Daily activities altera-
tion was most important in patients with severe psoriasis. A total of 36.8% of patients 
with severe psoriasis reported a negative impact on their professional life versus 19.6% 
for patients with mild psoriasis. Time devoted to phototherapy was on average 33 
hours/year/patient and the application of emollients took 25 hours/year/patient. 47.3% 
of patients had a feeling to clean the house more often, in correlation with the severity 
of the disease. Patients with severe psoriasis received more often aid from their family 
